Cantor Fitzgerald analyst Pablo Zuanic initiated CV Sciences (CVSI) with an Overweight rating, price target of $4.20 along with Charlotte's Web (CWBHF) and cbdMD (YCBD) at Neutral with respective price targets of $14.50 and $3.40 as part of his broader sector note on Consumer CBD. The analyst says the industry has risen 6-times in two years, reaching $4B in retail sales, and may reach as high as $25B over the next 5 years. Zuanic contends that while it is currently fragmented, the greater adoption of CBD products at big box retailers will likely lead to industry consolidation, helping the more established brands. In the short term however, the analyst still points to the lack of clear FDA guidelines on CBD sales, adding that near term catalysts on the industry are "to the downside".

In this week's "Rising High," The Fly's recurring series focused on cannabis and psychedelic stock news, The Fly looks back on study dosing, a completed acquisition and a research partnership. ATAI ANNOUNCES DOSING... To see the rest of the story go to thefly.com. See Story Here